Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-12-03 AGM Information
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
Management information circular - English.PDF
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) of Shareholders along with an Information Circular. It includes details about the meeting date, agenda items such as receiving audited financial statements, electing directors, appointing auditors, and ratifying a stock option plan. It also contains proxy solicitation information and voting instructions. The document is not the actual Annual Report or financial statements but rather the meeting notice and related materials for shareholders to vote on corporate matters. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length is substantial and contains detailed meeting and proxy information, confirming it is not a brief announcement or a report publication notice.
2020-12-03 English
Other.PDF
Regulatory Filings Classification · 95% confidence The document is a request form from BioVaxys Technology Corp. for shareholders to elect to receive financial statements and MD&A for the fiscal year 2019. It does not contain any actual financial data, analysis, or report content. Instead, it is a communication facilitating the distribution of reports. The document length is short (3696 characters) and it primarily serves as a request or notification form rather than a report or announcement of results. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory communication that does not fit other specific categories.
2020-12-03 English
Form of proxy - English.PDF
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for the Annual General Meeting (AGM) of BioVaxys Technology Corp. It includes appointment of proxyholders, voting instructions on director elections, appointment of auditors, and approval of stock option plans. The content is focused on shareholder voting procedures and proxy appointments for the AGM, not the AGM presentation materials themselves. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-12-03 English
News release - English.pdf
Regulatory Filings
2020-11-30 English
Material change report - English.pdf
Regulatory Filings
2020-11-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing positive preclinical study results for BioVaxys' SARS-CoV-2 vaccine candidate. It discusses experimental data from a murine model study, safety and tolerability, and future plans for regulatory approval of a Phase I human study. There are no financial statements, regulatory filings, or detailed financial performance data. The content is focused on scientific and clinical development updates rather than financial or governance information. It is not a report, transcript, or regulatory filing but a corporate announcement of study results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2020-11-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.